期刊文献+

氯沙坦对氧化型低密度脂蛋白受体影响的实验研究 被引量:1

An Experimental study of the Effects of Losartan on the Receptor of Low-densioy-lipoprotein
下载PDF
导出
摘要 目的 利用高脂饮食建立兔动脉粥样硬化模型 ,观察Lox 1在动脉组织中的表达和氯沙坦对Lox 1及斑块的影响。方法 将雄性新西兰白兔按体重随机分为 3组 :对照组 6只 ;高胆固醇组 8只 ;氯沙坦组 8只。检测 0、10周血脂水平 ;计算主动脉AS斑块面积 ;RT PCR法检测动脉组织中Lox 1mRNA表达的水平。结果 与正常对照组比较 ,高脂饮食增加血脂水平、斑块面积和Lox 1(mRNA)表达 (均P <0 .0 1)。应用氯沙坦后血脂较高胆固醇组无明显变化 (P >0 .0 5 ) ,而斑块面积、Lox 1表达不及高胆固醇组明显 (P <0 .0 1)。结论 Lox 1与动脉粥样硬化的发生、发展有着紧密的联系 ,高脂饮食促进Lox 1表达。氯沙坦可抑制Lox 1表达 ,具有抗AS的作用。 Objective To examine the expression of Lox-1 in aorta of cholesterol-fed rabbits and the effects of Losartan on etherosclerotic lesion and Lox-1. Methods 22 rabbits were divided into 3 groups: normal diet group, high-cholesterol group and Losartan group(25mg/kg·d). The blood samples were collected for cholesterol level at week 0 and week 10. LOX-1 expression in aortas was examined by semiquantitative RT-PCR. Results High-cholesterol diet induced hyperchol-esterolemia, formation of aortic lesion and increase in LOX-1 mRNA expression in the endothelium and neointima. Treatment with losartan decreased the enhanced LOX-1 expression. But the level of cholesterol did not alter significantly. Conclusion High-cholesterol diet induces the upregulation of LOX-1 expression in neointima of aortas of rabbits. Treatment with losartan, an AT1 blocker, markedly decreases this enhanced LOX-1 expression. Losartan has antiatherogenic effect.
出处 《医学新知》 CAS 2004年第1期40-43,共4页 New Medicine
关键词 氯沙坦 氧化型低密度脂蛋白受体 动脉粥样硬化 RT-PCR 血脂 血管紧张素 内皮细胞 Atherosclerosis Angiotensin II Lipoprotain Receptor
  • 相关文献

参考文献1

二级参考文献3

共引文献7

同被引文献23

  • 1董波,颜兆文,黄定九,陈玉英,宋怀东.氯沙坦对动脉粥样硬化兔金属蛋白酶基因表达的影响[J].上海第二医科大学学报,2004,24(12):1014-1016. 被引量:2
  • 2刘艳霞,林朝胜.血管紧张素Ⅱ受体拮抗剂对心血管的保护作用[J].心血管康复医学杂志,2005,14(5):498-500. 被引量:4
  • 3Miyazaki M,Takai S.Involvement of angiotensin I in development of atherosclerosis[J].Nippon Rinsho,2002,60:1904-1910.
  • 4Ross R.Atherosclerosis-An inflammatory disease[J].N Eng J Med,1999,340:115.
  • 5Marta RO,Lorenao O,Suzuki Y,et al.Proinflammatory actions of angiotensins[J].Curr Opin Nephrol Hypertens,2001,10(3):321-329.
  • 6Cipollone F,Fazia M,Iezzi A,et al.Blockade of the angiotensin Ⅱ type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity[J].Circulation,2004,109(12):1482-1488.
  • 7Proudfoot JM,Croft KD,Puddey IB,et al.Angiotensin Ⅱ type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1[J].Pharmacol Experiment Ther,2003,305(3):846-853.
  • 8Li Z,Iwai M,Liu HW,et al.Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker,valsartan,on atherosclerosis[J].Hypertension,2004,44(5):758-763.
  • 9Wu L,Iwai M,Nakaqami H,et al.Roles of angiotensin Ⅱ type 2 receptor stimulation associated with selective angiotensin Ⅱ type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury[J].Circulation,2001,27(22):2716-2721.
  • 10Xu ZG,Lanting L,Vazili ND,et al.Upregulation of angiotensin Ⅱ type 1 receptor,inflammatory mediators,and enzymes of arachidonate metabolism in obese Zucker rat kidney:reversal by angiotensin Ⅱ type 1 receptor blockade[J].Circulation,2005,111(15):1962-1969.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部